Mannan-binding lectin (MBL) production from human plasma.
Individuals with low levels of mannan-binding lectin (MBL) appear to be susceptible to infectious diseases. This suggests that substitution therapy with MBL might be a beneficial treatment of patients with MBL deficiency. A production process for an MBL product has been developed from a fraction II+III precipitate obtained by ethanol fractionation of plasma. The MBL process includes three chromatographic steps, where the first and key step is affinity chromatography on a cross-linked agarose matrix selecting for oligomeric, carbohydrate-binding MBL. The yield from the production process is about 25% of the plasma MBL content, and the purity is about 65%. The MBL product shows mannan-binding activity and complement-activating ability. A safety study has shown this plasma-derived MBL to be safe and well tolerated in adult MBL-deficient volunteers.
Laursen
I
I
Department of Research and Development, Division of Plasma Products, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark. inl@ssi.dk
D000047:Academies and Institutes; D005591:Chemical Fractionation / Q000379:methods; D017321:Clinical Trials, Phase I as Topic; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy; D037601:Mannose-Binding Lectin / Q000097:blood* / Q000172:deficiency / Q000302:isolation & purification / Q000627:therapeutic use
D037601:Mannose-Binding Lectin